Towards personalised anti-depressant therapy in pregnancy
Up to 10 % of women take antidepressant medication during pregnancy. However, half of them stop treatment in fear of the potential impact on the embryo. Treatment discontinuation increases the risk of relapse with profound consequences. Since evidence so far relies purely on epidemiological data, in order to determine the risk factors, the EU-funded PregnancyAD project will integrate demographics, clinical features and genetic data from a large representative population in Denmark. Addressing the genetics knowledge gap in the field will help identify women at high risk of relapse after discontinuing antidepressants during pregnancy. More importantly, it will contribute towards optimal antidepressant treatment recommendations during pregnancy.
Fields of science
Call for proposalSee other projects for this call
Funding SchemeMSCA-IF-GF - Global Fellowships
8000 Aarhus C
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
See on map